Background: Neuroinflammation plays a major role in the development of ischemic stroke, and regulation of the proinflammatory TLR4 signaling pathway in microglia stands to be a promising therapeutic strategy for stroke intervention. Recently, the homeostasis of mitochondrial dynamics has also been raised as a vital component in maintaining neuronal health, but its relevance in microglia hasn't been investigated. Schaftoside, a natural flavonoid compound and a promising treatment for inflammation, has demonstrated potency against LPS-induced lung inflammation in mice; however, its action on TLR4-induced neuroinflammation and mitochondrial dynamics in microglia is still unknown.
Methods: The effects of schaftoside in regulating inflammation and mitochondrial dynamics were investigated in vitro in oxygen glucose deprivation (OGD)-stimulated BV2 microglia cells.
Results: Schaftoside inhibited mRNA and protein expressions of proinflammatory cytokines (IL-1β, TNF-α, and IL-6) after 4 h in OGD-stimulated BV2 microglia cells, similar to the effect of TAK242, an inhibitor of TLR4. TLR4/Myd88 signaling pathway was effectively suppressed by schaftoside. In addition, both schaftoside and TAK242 treatments significantly decreased Drp1 expression, phosphorylation, translocation and mitochondrial fission in OGD-stimulated BV2 cells.
Conclusions: Our study suggested that schaftoside was able to reduce neuroinflammation, which is mediated in part by reducing TLR4/Myd88/Drp1-related mitochondrial fission in BV2 microglia cells.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jphs.2018.10.012 | DOI Listing |
Alzheimers Dement
December 2024
PCM Consulting, Pathways Connectivity Maps Inc., Mountain View, CA, USA.
Background: High-throughput assays have attracted significant attention in Alzheimer's Disease (AD) research, especially for enabling rapid diagnostics screening for factors at the molecular level contributing to the disease recurrence. With advances in laboratory automation, there is a growing need for quality pre-clinical data. Assays such as Microarrays, Proteomics, or AI are all dependent on high-quality input data that serve as a starting point.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Institute of Brain Sciene, National Yang Ming Chiao Tung University, Taipei, Taiwan.
Background: Amyloid-beta (Aβ) deposition is a key pathological characteristic of Alzheimer's disease (AD). Microglia serves as a crucial system responsible for clearing Aβ. Activated microglia migrate towards Aβ deposits, engulf them, and breakdown Aβ through cathepsins within the lysosome.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Yale University School of Medicine, New Haven, CT, USA.
Background: In neurodegenerative disease such as Alzheimer's disease and stroke, the brain transitions to pro-inflammatory profile, where microglia and T-cells in the brain have increase inflammatory profiles, along with increased Kv1.3 potassium channel abundance. Pharmacological blockade of Kv1.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Aligarh Muslim University, Aligarh, UttarPradesh, India.
Background: Following the genome-wide association studies (GWAS) discovery of microglia-specific genes, particularly Trem-2, SHIP-1, and CD33, significantly associated with higher Alzheimer's disease (AD) risk, the microglia TREM2 pathway has become central for regulating amyloid load, tissue damage, and limiting its spread. These discoveries have opened up the exciting possibility of therapeutic microglia TREM2 manipulation in AD. To date, however, several elements of TREM2 signaling remain unknown, ranging from the temporal activation pattern and receptor-ligand binding to modulation of the brain microenvironment.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Florey Institute of Neuroscience and Mental Health, Parkville, VIC, Australia.
Background: The reduced phagocytosis of amyloid β (Aβ) by microglia is linked to increased cognitive decline in Alzheimer's disease (AD) patients. Previous methods utilized anti-Aβ antibodies and flow cytometry to reveal Aβ surface binding without internalization. This study introduces a "Two-Color Fluorescent Reporting System" to overcome limitations, allowing differentiation between intra- and extracellular Aβ.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!